In addition to pancreatic cancer, He et al. showed that EGF receptor (EGFR) overexpression was associated with poor in vitro and in vivo responses to DRD2 antagonists [38], suggesting the mechanisms by which DRD2 signaling contributes to cancer progression appeared to be cell-type dependent. Here, DRD2 is linked to cancer.